Anti-PEG antibodies: Current situation and countermeasures
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Protein purification and stability · Inhalation and Respiratory Drug Delivery · Pharmaceutical studies and practices
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery10.1016/j.addr.2015.09.012 ↗
2. Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns10.1517/17425255.2014.967679 ↗
3. Facile separation of PEGylated liposomes enabled by anti-PEG scFv10.1021/acs.nanolett.1c03946 ↗
4. Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery10.1039/D1NR02065J ↗
5. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects10.1016/j.addr.2010.09.003 ↗
6. P.E.G.: will it come back to you? Polyethelyne glycol immunogenicity, COVID vaccines, and the case for new PEG derivatives and alternatives10.3389/fbioe.2022.879988 ↗
7. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins10.1159/000233309 ↗
8. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors10.1159/000233512 ↗
9. Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies10.1021/acsnano.1c05922 ↗
10. Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: appearance of an unexplained mechanism in the ABC phenomenon10.1016/j.jconrel.2020.04.011 ↗
11. The mechanisms of anti-PEG immune response are different in the spleen and the lymph nodes10.1016/j.jconrel.2022.12.005 ↗
12. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage10.1016/j.jconrel.2013.07.026 ↗
13. Pseudo-anaphylaxis to polyethylene glycol (PEG)-coated liposomes: roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions10.1021/acsnano.9b03942 ↗
14. Antibodies against poly(ethylene glycol) activate innate immune cells and induce hypersensitivity reactions to PEGylated nanomedicines10.1021/acsnano.2c12193 ↗
15. Premature drug release from polyethylene glycol (PEG)-coated liposomal doxorubicin via formation of the membrane attack complex10.1021/acsnano.9b07218 ↗
16. State of the art in PEGylation: the great versatility achieved after forty years of research10.1016/j.jconrel.2011.10.037 ↗
17. Long-term safety of PEGylated coagulation factor VIII in the immune-deficient rowett nude rat10.1155/2017/8496246 ↗
18. The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A10.1182/bloodadvances.2022007529 ↗
19. Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker10.1111/bjh.16254 ↗
20. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients10.1186/ar4500 ↗
21. Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals10.1016/j.addr.2020.07.024 ↗
22. Immunological properties of uricase conjugated to neutral soluble polymers10.1021/bc000119x ↗
23. Impact of pre-existing or induced anti-PEG IgM on the pharmacokinetics of peginterferon Alfa-2a (Pegasys) in mice10.1021/acs.molpharmaceut.0c00366 ↗
24. Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice10.1016/j.ejpb.2020.04.026 ↗
25. Anti-PEG antibodies inhibit the anticoagulant activity of PEGylated aptamers10.1016/j.chembiol.2019.02.001 ↗
26. Immunogenicity: clouding the future of intravitreal therapy10.1080/09273948.2022.2139273 ↗
27. Clinical impact of antipolyethylene glycol (PEG) antibody in hematological patients administered PEGylated-granulocyte colony-stimulating factor10.1002/cpdd.1225 ↗
28. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout10.1186/ar4497 ↗
29. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase
30. PEGylated liposomes: immunological responses10.1080/14686996.2019.1627174 ↗
31. Accelerated blood clearance phenomenon reduces the passive targeting of PEGylated nanoparticles in peripheral arterial disease10.1021/acsami.6b05840 ↗
32. Accelerated blood clearance of lipid nanoparticles entails a biphasic humoral response of B-1 followed by B-2 lymphocytes to distinct antigenic moieties10.4049/immunohorizons.1900029 ↗
33. Investigating generation of antibodies against the lipid nanoparticle vector following COVID-19 vaccination with an mRNA vaccine10.1021/acs.molpharmaceut.2c01036 ↗
34. The importance of poly(ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation10.3390/polym12020298 ↗
35. Anti-PEG immunity: emergence, characteristics, and unaddressed questions10.1002/wnan.1339 ↗
36. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species10.1002/jps.23254 ↗
37. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes10.1016/j.ejpb.2018.02.019 ↗
38. Time interval of two injections and first-dose dependent of accelerated blood clearance phenomenon induced by PEGylated liposomal gambogenic acid: the contribution of PEG-specific IgM10.1016/j.xphs.2018.10.027 ↗
39. Ex-vivo/in-vitro anti-polyethylene glycol (PEG) immunoglobulin M production from murine splenic B cells stimulated by PEGylated liposome10.1248/bpb.b13-00562 ↗
40. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: faster PEG shedding attenuates anti-PEG IgM production10.1016/j.ijpharm.2020.119792 ↗
41. Physicochemical properties, pharmacokinetics, toxicology and application of nanocarriers10.1039/D2TB02001G ↗
42. Enhanced immunocompatibility of ligand-targeted liposomes by attenuating natural IgM absorption10.1038/s41467-018-05384-1 ↗
43. Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin10.1016/j.ijpharm.2014.09.047 ↗
44. Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan10.1016/j.ijpharm.2013.01.012 ↗
45. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes10.1016/j.ymthe.2005.09.014 ↗
46. Accelerated blood clearance and hypersensitivity by PEGylated liposomes containing TLR agonists10.1016/j.jconrel.2021.12.033 ↗
47. Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines10.1038/s41577-022-00825-x ↗
48. Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine)10.1016/j.jconrel.2022.12.039 ↗
49. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine10.1021/acsnano.2c04543 ↗
50. Monitoring anti-PEG antibodies level upon repeated lipid nanoparticle-based COVID-19 vaccine administration10.3390/ijms23168838 ↗
51. High prevalence of pre-existing antibodies against polyethylene glycol (PEG) in hepatitis C (HCV) patients which is not associated with impaired response to peg-interferon10.1016/S0168-8278(10)60309-1 ↗
52. Antibodies against polyethylene glycol in human blood: a literature review10.1016/j.vascn.2020.106678 ↗
53. Responses: cell interaction dynamics and decisions10.1016/j.cell.2019.03.016 ↗
54. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen10.1038/ni.2194 ↗
55. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD8810.1038/ni.1914 ↗
56. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs10.1016/j.ijpharm.2012.07.049 ↗
57. Species and sex differences in the blood clearance and immunogenicity of PEGylated uricase: a comparative 26-week toxicity study in rats and monkeys10.1016/j.lfs.2019.116892 ↗
58. Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase
59. Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: effects of polymer dose, PEG coating, and encapsulated anticancer drug10.1007/s11095-012-0934-y ↗
60. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation10.1002/pbc.26686 ↗
61. A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol10.1038/s41467-017-00622-4 ↗
62. IgM memory B cells: a mouse/human paradox10.1007/s00018-012-0971-z ↗
63. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients10.1002/cncr.22739 ↗
64. Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals10.1021/acs.analchem.6b03109 ↗
65. Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population10.1021/acs.analchem.6b03437 ↗
66. The mystery of antibodies against polyethylene glycol (PEG) - what do we know?10.1007/s11095-016-1961-x ↗
67. A generic method for the detection of polyethylene glycol specific IgG and IgM antibodies in human serum10.1016/j.jim.2019.112669 ↗
68. Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma10.1016/j.toxrep.2020.12.022 ↗
69. Aging and the immune system: an overview10.1016/j.jim.2018.08.005 ↗
70. Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products10.1016/j.jconrel.2022.09.031 ↗
71. Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: evidence for immunogenicity of PEG10.1016/j.vaccine.2023.06.009 ↗
72. Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice10.1016/j.jconrel.2023.01.012 ↗
73. Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients10.1016/j.jconrel.2023.09.003 ↗
74. Anti-PEG antibodies in the clinic: current issues and beyond PEGylation10.1016/j.jconrel.2016.06.040 ↗
75. Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies10.1021/bc100067t ↗
76. A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays10.1016/j.jpba.2011.04.006 ↗
77. Anti-PEG antibodies enriched in the protein corona of PEGylated nanocarriers impact the cell uptake10.1039/D3NH00198A ↗
78. Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics10.1016/j.drudis.2014.08.015 ↗
79. Complement activation: a potential threat on the safety of poly(ethylene glycol)-coated nanomedicines10.1021/acsnano.0c03648 ↗
80. Exploring the relationship between anti-PEG IgM behaviors and PEGylated nanoparticles and its significance for accelerated blood clearance10.1016/j.jconrel.2016.05.010 ↗
81. Anti-polyethylene glycol antibodies alter the protein corona deposited on nanoparticles and the physiological pathways regulating their fate in vivo10.1016/j.jconrel.2018.08.022 ↗
82. A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor10.1007/s11357-021-00495-y ↗
83. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement10.1016/j.jconrel.2021.11.042 ↗
84. Understanding the role of Anti-PEG antibodies in the complement activation by doxil in vitro10.3390/molecules23071700 ↗
85. Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial10.1177/1756285616633967 ↗
86. Interrogating preclinical study of liposomes: the effect of mouse strain reexamined10.1016/j.jconrel.2021.04.025 ↗
87. Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination10.1016/j.vaccine.2023.05.029 ↗
88. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: a report from the Children's Oncology Group
89. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin10.1001/archderm.136.12.1475 ↗
90. Reactive oxygen species-mediated inflammation and apoptosis in hand-foot syndrome induced by PEGylated liposomal doxorubicin10.2147/IJN.S280187 ↗
91. Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs10.1177/096032719901800103 ↗
92. Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines10.1038/s41565-022-01071-x ↗
93. Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia10.3324/haematol.2020.258525 ↗
94. Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer10.1016/j.jaci.2015.10.034 ↗
95. mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations10.1016/j.vaccine.2022.08.024 ↗
96. Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice10.1016/j.ejps.2016.06.007 ↗
97. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function10.1152/ajpheart.00622.2005 ↗
98. The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review10.1016/j.semarthrit.2021.01.005 ↗
99. Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles10.1038/nnano.2016.135 ↗
100. Development of ImmTOR tolerogenic nanoparticles for the mitigation of anti-drug antibodies10.3389/fimmu.2020.00969 ↗